Inozyme Pharma (INZY) AI Stock Analysis

• Market Cap: $61.96M
• Dividend Yield: N/A
• Average Volume (3M): 442.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: N/A
• EPS Growth: -17.06%
• Country: US
• Employees: 67
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -1.62
• Shares Outstanding: 64,240,200
• 10 Day Avg. Volume: 417,012
• 30 Day Avg. Volume: 442,604
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 3.97
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.29
• Price Target Upside: 1055.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

Inozyme Pharma's overall stock score reflects its early-stage biotechnology status, with no revenue and significant operational losses. Despite having manageable debt and reasonable cash reserves, the company's financial performance is weak. The technical analysis indicates some short-term buying interest, but the stock remains below key long-term averages, signaling caution. Valuation metrics are less meaningful due to the negative earnings, highlighting the speculative nature of this investment.

Positive Factors

Clinical Trial Progress

INZ-701 is in Phase 3 development, indicating progress in clinical trials for ENPP1 Deficiency treatment.

Interim Data

Inozyme announced positive interim data from its global, open-label Phase 1b ENERGY-1 trial and Expanded Access Program evaluating INZ-701 in infants and young children with ENPP1 Deficiency.

Regulatory Designation

INZ-701 has orphan drug designation from the EMA and the FDA for the treatment of ENPP1 Deficiency.

Negative Factors

Financial Performance

Inozyme reported Q4 results including a $27MM net loss and net cash of $113MM.

Price Target Adjustment

Lowering the price target to $15 from $23.

Workforce Reduction

De-prioritization of the ABCC6 and Calciphylaxis programs and a ~25% workforce reduction to conserve cash.

Inozyme Pharma Business Overview & Revenue Model

Company Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Inozyme Pharma makes money primarily through the development and commercialization of its proprietary therapies aimed at treating rare mineralization disorders. The company's revenue model includes potential income from product sales, should its therapies receive regulatory approval and reach the market. Additionally, Inozyme may engage in partnerships or collaborations with larger pharmaceutical companies to co-develop products or out-license their technologies, which could provide upfront payments, milestone payments, and royalties. As a company focused on clinical-stage development, Inozyme may also receive funding through research grants and investments to support ongoing clinical trials and further drug development.

Inozyme Pharma Financial Statement Overview

Summary

Inozyme Pharma is in a typical early-stage biotechnology phase, characterized by zero revenue and significant operational losses. While its cash reserves and manageable debt levels provide some financial resilience, the ongoing negative cash flows and lack of revenue generation highlight the need for successful product development and commercialization to ensure long-term viability.

Income Statement

Inozyme Pharma has consistently reported zero revenue over the years, indicating its early-stage status typical in biotechnology. The company has faced increasing EBIT and net income losses over the years, highlighting challenges in managing operational efficiency and profitability.

Balance Sheet

The company has a relatively low debt-to-equity ratio, suggesting prudent leverage management. However, declining stockholders' equity and increasing liabilities could pose risks to financial stability. Despite this, the company maintains a healthy cash position.

Cash Flow

Operating cash flow has become increasingly negative over the years, reflecting operational cash burn, which is common in biotech firms without revenue. Despite negative free cash flow, the company has managed to raise significant financing cash flows, mitigating liquidity concerns temporarily.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-1.29M	-1.18M	-1.05M	-217.00K
	EBIT
-104.03M	-75.64M	-68.67M	-56.65M	-57.04M
	EBITDA
-104.03M	-74.81M	-65.88M	-55.97M	-56.82M
	Net Income Common Stockholders
-102.02M	-71.17M	-65.45M	-56.41M	-55.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
113.09M	188.59M	127.87M	111.80M	159.90M
	Total Assets
123.18M	200.85M	139.19M	123.54M	169.36M
	Total Debt
15.41M	46.59M	6.78M	3.37M	1.29M
	Net Debt
-5.67M	12.00M	-26.14M	-19.95M	-158.61M
	Total Liabilities
65.36M	60.37M	20.80M	14.27M	11.26M
	Stockholders Equity
57.83M	140.48M	118.59M	109.27M	158.10M
Cash Flow		Free Cash Flow
-91.97M	-70.97M	-58.17M	-48.55M	-36.54M
	Operating Cash Flow
-91.91M	-70.67M	-57.76M	-48.15M	-35.97M
	Investing Cash Flow
67.00M	-53.65M	-5.40M	42.80M	-117.18M
	Financing Cash Flow
11.40M	125.97M	72.79M	609.00K	149.81M

Inozyme Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.15
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INZY, the sentiment is Positive. The current price of 1.15 is above the 20-day moving average (MA) of 0.95, above the 50-day MA of 1.03, and below the 200-day MA of 3.18, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.25 is Neutral, neither overbought nor oversold. The STOCH value of 67.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INZY.

Inozyme Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.38B	3.59	-41.63%	2.87%	17.72%	1.87%
ADAP	45 Neutral	$70.82M	―	-273.36%	―	194.23%	45.50%
INZY	44 Neutral	$61.96M	―	-102.90%	―	―	-17.06%
IOBT	43 Neutral	$62.59M	―	-106.00%	―	―	32.77%
PYXS	42 Neutral	$67.75M	―	-62.75%	―	―	30.51%
VTVT	38 Underperform	$73.90M	―	-121.97%	―	―	65.54%
INO	33 Underperform	$69.31M	―	-115.42%	―	-73.83%	34.81%

Inozyme Pharma Corporate Events

Inozyme Pharma Advances with Promising Trial Results

Inozyme Pharma announced positive interim results for its INZ-701 treatment from the ENERGY 1 trial and Expanded Access Program, demonstrating improved survival rates, reduced arterial calcifications, and improved heart function in infants and young children with ENPP1 Deficiency. The company completed enrollment in the ENERGY 3 pivotal trial and received regulatory guidance for the upcoming ASPIRE pivotal trial focused on ABCC6 Deficiency in children, highlighting significant advancements in their therapeutic programs and underscoring the potential impact on addressing unmet medical needs in these patient populations.